相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HIF-1 at the crossroads of hypoxia, inflammation, and cancer
Kuppusamy Balamurugan
INTERNATIONAL JOURNAL OF CANCER (2016)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor
Shin Foong Ngiow et al.
CANCER RESEARCH (2016)
Germline NLRP1 Mutations Cause Skin Inflammatory and Cancer Susceptibility Syndromes via Inflammasome Activation
Franklin L. Zhong et al.
CELL (2016)
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Camille Guillerey et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
Cora Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
The ever-expanding role of HIF in tumour and stromal biology
Edward L. LaGory et al.
NATURE CELL BIOLOGY (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Megan M. Kaneda et al.
CANCER DISCOVERY (2016)
Antitumour actions of interferons: implications for cancer therapy
Belinda S. Parker et al.
NATURE REVIEWS CANCER (2016)
Aspirin and colorectal cancer: the promise of precision chemoprevention
David A. Drew et al.
NATURE REVIEWS CANCER (2016)
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
E. M. Dijkgraaf et al.
ANNALS OF ONCOLOGY (2015)
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Santiago Zelenay et al.
CELL (2015)
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
Michele Cioffi et al.
CLINICAL CANCER RESEARCH (2015)
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
Stefano Ugel et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Inflammasomes: mechanism of action, role in disease, and therapeutics
Haitao Guo et al.
NATURE MEDICINE (2015)
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David Hong et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages
Aya Kakizaki et al.
ONCOIMMUNOLOGY (2015)
Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Donald T. Weed et al.
CLINICAL CANCER RESEARCH (2015)
Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer
Kimmie Ng et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
Holly E. Barker et al.
NATURE REVIEWS CANCER (2015)
The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target
A. Neil Barclay et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
Jesus San-Miguel et al.
BLOOD (2014)
Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
Laura Tornatore et al.
CANCER CELL (2014)
Mechanisms of action of tasquinimod on the tumour microenvironment
E. Raymond et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors
Woondong Jeong et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Eric Angevin et al.
CLINICAL CANCER RESEARCH (2014)
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Matjaz Rokavec et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma
Tobias Bald et al.
NATURE (2014)
Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Tobias Bald et al.
CANCER DISCOVERY (2014)
Targeting Cancer-Derived Adenosine: New Therapeutic Approaches
Arabella Young et al.
CANCER DISCOVERY (2014)
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
Jing Liu et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
John Mascarenhas et al.
BLOOD (2013)
Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma
Xi Wu et al.
CANCER LETTERS (2013)
Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2013)
Tumor Necrosis Factor-α Blocks Differentiation and Enhances Suppressive Activity of Immature Myeloid Cells during Chronic Inflammation
Moshe Sade-Feldman et al.
IMMUNITY (2013)
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Kenneth J. Pienta et al.
INVESTIGATIONAL NEW DRUGS (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Cancer risk in immune-mediated inflammatory diseases (IMID)
Rudi Beyaert et al.
MOLECULAR CANCER (2013)
Disrupting Cytokine Signaling in Pancreatic Cancer A Phase I/II Study of Etanercept in Combination With Gemcitabine in Patients With Advanced Disease
Christina Wu et al.
PANCREAS (2013)
Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue
Stephen D. Hursting et al.
NUTRITION AND PHYSICAL ACTIVITY IN AGING, OBESITY, AND CANCER (2012)
Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
Yuliya Pylayeva-Gupta et al.
CANCER CELL (2012)
Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State
Michele W. L. Teng et al.
CANCER RESEARCH (2012)
NF-κB and the link between inflammation and cancer
Joseph A. DiDonato et al.
IMMUNOLOGICAL REVIEWS (2012)
Regulation of Immune Responses by Prostaglandin E-2
Pawel Kalinski
JOURNAL OF IMMUNOLOGY (2012)
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis
Catherine de Martel et al.
LANCET ONCOLOGY (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
Receptor Tyrosine Kinases and TLR/IL1 Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
Michael C. Schmid et al.
CANCER CELL (2011)
Tumor Promotion via Injury- and Death-Induced Inflammation
Ali Kuraishy et al.
IMMUNITY (2011)
IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
Seigo Terawaki et al.
JOURNAL OF IMMUNOLOGY (2011)
Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
David G. DeNardo et al.
CANCER DISCOVERY (2011)
HMGB1 and RAGE in Inflammation and Cancer
Gary P. Sims et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
J. M. G. Larkin et al.
BRITISH JOURNAL OF CANCER (2010)
TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion
Y. Wu et al.
BRITISH JOURNAL OF CANCER (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Tanya B. Dorff et al.
CLINICAL CANCER RESEARCH (2010)
Sterile inflammation: sensing and reacting to damage
Grace Y. Chen et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Francesco Colotta et al.
CARCINOGENESIS (2009)
The COX-2/PGE(2) pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment
Alexander Greenhough et al.
CARCINOGENESIS (2009)
Development of HIF-1 inhibitors for cancer therapy
Barbara Onnis et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Treatment of rheumatoid arthritis: state of the art 2009
Ronald F. van Vollenhoven
NATURE REVIEWS RHEUMATOLOGY (2009)
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
John A. Lust et al.
MAYO CLINIC PROCEEDINGS (2009)
The metastatic niche: adapting the foreign soil
Bethan Psaila et al.
NATURE REVIEWS CANCER (2009)
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
Pingyan Cheng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells
Pratima Sinha et al.
JOURNAL OF IMMUNOLOGY (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase
Sachie Hiratsuka et al.
NATURE CELL BIOLOGY (2008)
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Patrizia Pellegatti et al.
PLOS ONE (2008)
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel et al.
NATURE (2007)
Tumor necrosis factor α as a new target for renal cell carcinoma:: Two sequential phase II trials of infliximab at standard and high dose
Michelle L. Harrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas
Kaiming Xu et al.
CANCER RESEARCH (2007)
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
Paolo Serafini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer
S Madhusudan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A genetically defined model for human ovarian cancer
JS Liu et al.
CANCER RESEARCH (2004)
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
SC Wang et al.
CANCER CELL (2004)
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
A Sparmann et al.
CANCER CELL (2004)
A phase II study of etanercept (enbrel), a tumor necrosis factor α inhibitor in patients with metastatic breast cancer
S Madhusudan et al.
CLINICAL CANCER RESEARCH (2004)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Inflammation and cancer: back to Virchow?
F Balkwill et al.
LANCET (2001)
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
A Taguchi et al.
NATURE (2000)
分享论文
